98 related articles for article (PubMed ID: 17450472)
21. Adynamic ileus in a patient with non-small-cell lung cancer after treatment with vinorelbine.
Liebmann J; Friedman K
Am J Med; 1996 Dec; 101(6):658-9. PubMed ID: 9003116
[No Abstract] [Full Text] [Related]
22. Combination of polymorphisms within 5' and 3' untranslated regions of thymidylate synthase gene modulates survival in 5 fluorouracil-treated colorectal cancer patients.
Fernández-Contreras ME; Sánchez-Hernández JJ; González E; Herráez B; Domínguez I; Lozano M; García De Paredes ML; Muñoz A; Gamallo C
Int J Oncol; 2009 Jan; 34(1):219-29. PubMed ID: 19082493
[TBL] [Abstract][Full Text] [Related]
23. Randomized trial of drip infusion versus bolus injection of vinorelbine for the control of local venous toxicity.
Yoh K; Niho S; Goto K; Ohmatsu H; Kubota K; Kakinuma R; Saijo N; Nishiwaki Y
Lung Cancer; 2007 Mar; 55(3):337-41. PubMed ID: 17126951
[TBL] [Abstract][Full Text] [Related]
24. Prognostic impact of p53 Pro72 homozygous genotype in non-small cell lung cancer patients.
Boldrini L; Gisfredi S; Ursino S; Lucchi M; Greco G; Mussi A; Fontanini G
Oncol Rep; 2008 Mar; 19(3):771-3. PubMed ID: 18288414
[TBL] [Abstract][Full Text] [Related]
25. Association of EcoRI polymorphism of the metastasis-suppressor gene NME1 with susceptibility to and severity of non-small cell lung cancer.
Hsieh YS; Lee YL; Yang SF; Yang JS; Chen W; Chen SC; Shih CM
Lung Cancer; 2007 Nov; 58(2):191-5. PubMed ID: 17688968
[TBL] [Abstract][Full Text] [Related]
26. Oral versus intravenous administration of vinorelbine as a single agent for the first-line treatment of metastatic nonsmall cell lung carcinoma (NSCLC): A randomized phase II trial.
Hirsh V; Desjardins P; Needles BM; Rigas JR; Jahanzeb M; Nguyen L; Zembryki D; Leopold LH
Am J Clin Oncol; 2007 Jun; 30(3):245-51. PubMed ID: 17551300
[TBL] [Abstract][Full Text] [Related]
27. Lung cancer susceptibility and prognosis associated with polymorphisms in the nonhomologous end-joining pathway genes: a multiple genotype-phenotype study.
Tseng RC; Hsieh FJ; Shih CM; Hsu HS; Chen CY; Wang YC
Cancer; 2009 Jul; 115(13):2939-48. PubMed ID: 19408343
[TBL] [Abstract][Full Text] [Related]
28. MDR1 polymorphisms predict the response to etoposide-cisplatin combination chemotherapy in small cell lung cancer.
Sohn JW; Lee SY; Lee SJ; Kim EJ; Cha SI; Kim CH; Lee JT; Jung TH; Park JY
Jpn J Clin Oncol; 2006 Mar; 36(3):137-41. PubMed ID: 16478794
[TBL] [Abstract][Full Text] [Related]
29. Matrix metalloproteinase polymorphisms and survival in stage I non-small cell lung cancer.
Heist RS; Marshall AL; Liu G; Zhou W; Su L; Neuberg D; Lynch TJ; Wain J; Christiani DC
Clin Cancer Res; 2006 Sep; 12(18):5448-53. PubMed ID: 17000679
[TBL] [Abstract][Full Text] [Related]
30. [Combined effects of genetic polymorphisms in cytochrome P450s and GSTM1 on lung cancer susceptibility].
Gu YF; Zhang ZD; Zhang SC; Zheng SH; Jia HY; Gu SX
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(43):3064-8. PubMed ID: 18261353
[TBL] [Abstract][Full Text] [Related]
31. The relationship between polymorphisms of genes regulating DNA repair or cell division and the toxicity of platinum and vinorelbine chemotherapy in advanced NSCLC patients.
Powrózek T; Mlak R; Krawczyk P; Homa I; Ciesielka M; Kozioł P; Prendecka M; Milanowski J; Małecka-Massalska T
Clin Transl Oncol; 2016 Feb; 18(2):125-31. PubMed ID: 26193985
[TBL] [Abstract][Full Text] [Related]
32. Clinical outcomes of oral metronomic vinorelbine in advanced non-small cell lung cancer: correlations with pharmacokinetics and MDR1 polymorphisms.
Gusella M; Pasini F; Caruso D; Barile C; Modena Y; Fraccon AP; Bertolaso L; Menon D; Crepaldi G; Bononi A; Spezzano R; Telatin GA; Corona G; Padrini R
Cancer Chemother Pharmacol; 2019 Mar; 83(3):493-500. PubMed ID: 30542768
[TBL] [Abstract][Full Text] [Related]
33. [The incidence of phlebitis in the patients administrated vinorelbine by intravenous bolus injection--a retrospective study].
Nakayama S; Matsubara N; Sakai T; Aso N
Gan To Kagaku Ryoho; 2002 Apr; 29(4):633-5. PubMed ID: 11977554
[No Abstract] [Full Text] [Related]
34. Dexamethasone as a probe for vinorelbine clearance.
Puisset F; Dalenc F; Chatelut E; Cresteil T; Lochon I; Tisnes P; Roché H
Br J Clin Pharmacol; 2005 Jul; 60(1):45-53. PubMed ID: 15963093
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of telomerase polymorphism in non-small cell lung cancer.
Catarino R; Araújo A; Coelho A; Gomes M; Nogueira A; Lopes C; Medeiros RM
Clin Cancer Res; 2010 Jul; 16(14):3706-12. PubMed ID: 20606038
[TBL] [Abstract][Full Text] [Related]
36. [Correlation of the sensitivity of NP chemotherapy in non-small lung cancer with DNA repair gene XRCC1 polymorphism].
Hong CY; Xu Q; Yue Z; Zhang Y; Yuan Y
Ai Zheng; 2009 Dec; 28(12):1291-7. PubMed ID: 19958624
[TBL] [Abstract][Full Text] [Related]
37. Genetic polymorphism of cytochrome P450 3A5 in Chinese.
Chou FC; Tzeng SJ; Huang JD
Drug Metab Dispos; 2001 Sep; 29(9):1205-9. PubMed ID: 11502729
[TBL] [Abstract][Full Text] [Related]
38. Significant impact of IL-6 -174G/C but inverse relation with -634 C/G polymorphism in patients with non-small cell lung cancer in Kashmiri population.
Bhat IA; Qasim I; Masoodi KZ; Paul SA; Bhat BA; Rasool R; Aziz SA; Shah ZA
Immunol Invest; 2015; 44(4):349-60. PubMed ID: 25942346
[TBL] [Abstract][Full Text] [Related]
39. Polymorphism of CYP450 and cancer susceptibility.
Han XM; Zhou HH
Acta Pharmacol Sin; 2000 Aug; 21(8):673-9. PubMed ID: 11501173
[TBL] [Abstract][Full Text] [Related]
40. [Association between Ephb4 gene polymorphism and non-small cell lung cancer].
Shen LQ; Wang XC; Zhao J
Zhonghua Zhong Liu Za Zhi; 2009 Oct; 31(10):778-9. PubMed ID: 20021833
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
